Salute e Benessere
Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types
Ona has appointed , an internationally recognized leader in precision oncology with an outstanding track record in cancer research, biomarker development, and clinical trials, as Chair of the Advisory Board. In collaboration with Ona's Advisor, , he has been instrumental in identifying the target of ONA-255 and functionally validating it, working alongside the expert team at Ona. Their combined efforts have generated critical preclinical data to support the clinical development of ONA-255. This important data which has been exclusively licensed to Ona from FCRB-IDIBAPS, IRB Barcelona, UB and ICREA, bolsters the foundation for ONA-255's progression. Dr. Prat serves as the Director of the Clínic Barcelona Comprehensive Cancer Center, Professor of Medicine at the University of Barcelona , and is Co-Founder and Chief Scientific Officer of REVEAL GENOMICS .
With over 300 peer-reviewed publications and leadership roles in oncology research, clinical trials, and precision medicine initiatives, Dr. Prat has been at the forefront of developing and translating novel therapies and diagnostic tools into clinical practice.
joins as Chief Medical Officer and brings extensive experience in translational medicine, clinical and medical development, and pharmacovigilance for innovative biologics. She previously held multiple managerial and senior clinical roles at Sandoz, MorphoSys, and Otsuka Novel Products. She holds a medical license and a Doctor of Medicine from the University of Munich and holds an MBA from the University of Applied Science.
has been appointed Chief Financial Officer. With over two decades of experience in finance, business development, investor relations, and private equity, Stéphane brings a wealth of expertise. He spent nine years at Ipsen, first as Vice President and Head of Investor Relations before advancing to CFO of Ipsen Iberia. His career also includes the role of CFO and Head of Alliances & Business Development at Lysogene, a Phase 3 gene therapy company listed on Euronext, roles in private equity at LaSalle Investment Management and Calyon Americas, and as a sell-side research analyst at Exane BNP Paribas. Stéphane simultaneously serves as CFO at Corteria Pharmaceuticals.
He holds an MSc in Accounting and Finance from the London School of Economics (LSE), an MSc in Management from Paris Dauphine University, and an Executive Leadership degree from Harvard Business School .
, "ADCs have transformed cancer treatment; however, the technology has been applied to a limited number of tumor targets. These limitations restrict the number of patients who can benefit from treatments and highlight the critical need to identify new broadly expressed tumor targets. Ona's tailor-designed ADCs have the potential to define new treatment paradigms and patient populations. With the expansion of our executive team and advisory board, Ona is well-positioned to execute our strategic vision to develop multiple first-in-class ADCs and advance our pipeline into clinical development to improve clinical results across multiple tumor types in patients."
: "Ona's cutting-edge technology has the potential to redefine treatments for aggressive and refractory cancers. As a strong advocate for precision oncology, I am committed to driving the development of novel, targeted therapies that improve patient outcomes. I am honored to contribute my expertise to this groundbreaking innovation."
Ona Therapeutics is pioneering the development of first-in-class antibody-drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. As a spin-off of both IRB and ICREA, Ona collaborates with renowned academics, clinicians, and clinical research partners. This collaborative approach enables the identification of novel therapeutic targets derived from the unique biology of treatment-refractory advanced cancer patients. Ona's approach combines biological insight with expertise in biologics to design ADCs and antibody therapies using target validation, optimized payload design, and validated linker-payload technology to provide effective treatments for patients with limited options. Its precision-engineered ADC pipeline consists of first-in-class ADCs, targeting aggressive and refractory cancer indications. The lead ADC, ONA-255, targeting breast cancer and solid tumors is in active IND development with planned clinical submissions by the end of 2025. The company is also expanding its target indications into additional aggressive cancer types, including gastric, liver, and colon cancers. For further information visit our new website here https://ona-therapeutics.com/.
View original content:https://www.prnewswire.co.uk/news-releases/ona-therapeutics-strengthens-leadership-team-to-accelerate-first-in-class-adcs-into-clinical-development-across-cancer-types-302379077.html